Your session is about to expire
← Back to Search
Drug + Behavioral Weight Loss for Obesity (A-NEW Trial)
A-NEW Trial Summary
This trial will study the effects of a weight loss drug and behavior intervention on weight loss in obese breast cancer survivors, and how weight loss affects biomarkers and gut microbiome.
A-NEW Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.A-NEW Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am enrolled or plan to enroll in a weight loss program or take weight loss medication.You have a serious medical condition that could make it hard to measure your weight accurately, or a condition that makes weight loss unsafe. This includes conditions like active cancer, kidney disease, liver disease, autoimmune disease, and uncontrolled high blood pressure.I am fully active or can carry out light work.I haven't taken excluded medications recently and any current meds have been stable for 3+ months.I am a woman who finished my local cancer treatment at least 3 months ago.I have been treated for diabetes with insulin or sulfonylureas in the last 3 months.My BMI is over 27 and I have hypertension, diabetes, or high cholesterol, and I weigh less than 400 lbs.I was diagnosed with early-stage breast cancer or DCIS within the last 10 years.You are struggling with alcohol, nicotine, or drug addiction, or have recently stopped taking certain medications suddenly.You have a mental health condition that is not currently stable, or you have bulimia or anorexia nervosa.
- Group 1: FAST-BWL
- Group 2: SLOW-BWL
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What was the outcome of Contrave's FDA evaluation?
"At Power, we give Contrave a safety score of 2. This is because Phase 2 trials only have data supporting safety, and no efficacy data has been collected yet."
What is the standard medical protocol for Contrave?
"Contrave has demonstrated efficacy in the treatment of attention deficit hyperactivity disorder (ADHD), seasonal affective disorder, and smoking cessation."
Are there any available slots for new participants in this research project?
"That is correct, the trial information on clinicaltrials.gov does show that the study is looking for more participants. The listing was created on February 8th, 2021 and was last updated November 2nd, 2022. They are hoping to enroll 55 people total at a single site."
How many people can join this trial at most?
"Yes, an analysis of the information on clinicaltrials.gov reveals that this study is still enrolling patients. This research was initially made public on February 8th, 2021 and received its most recent update November 2nd, 2022. The trial requires 55 participants from a single location."
Share this study with friends
Copy Link
Messenger